Stay updated on PLACARD Trial: CXD101 + Pembrolizumab in DLBCL

Sign up to get notified when there's something new on the PLACARD Trial: CXD101 + Pembrolizumab in DLBCL page.
Latest website image capture
Clouds background image

Latest updates to the PLACARD Trial: CXD101 + Pembrolizumab in DLBCL page

  1. Check
    5 days ago
    Change Detected
    Summary
    Both screenshots show the same study details and status; there are no additions or deletions to core content such as the trial title, conditions, eligibility, or outcomes.
    Difference
    0.4%
    Check dated 2025-11-03T00:45:03.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    34 days ago
    Change Detected
    Summary
    Core page content updated with a government operating status notice and a new resource topic; software revision updated from v3.1.0 to v3.2.0. No other significant changes.
    Difference
    3%
    Check dated 2025-10-05T06:34:39.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    Major change: version updated to v3.1.0 with removal of a specific disease resource (Diffuse large B-cell lymphoma) from the Genetics and Rare Diseases Information Center; no new substantive content added.
    Difference
    0.5%
    Check dated 2025-09-28T02:51:39.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    Updated page revision from v3.0.1 to v3.0.2. Removed the Back to Top navigation element.
    Difference
    0.2%
    Check dated 2025-09-13T16:55:09.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.
    Difference
    0.2%
    Check dated 2025-09-06T14:19:48.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the addition of new medical terms and disease classifications related to diffuse large B-cell lymphoma, while also removing several related terms and location details.
    Difference
    4%
    Check dated 2025-08-30T11:11:56.000Z thumbnail image

Stay in the know with updates to PLACARD Trial: CXD101 + Pembrolizumab in DLBCL

Enter your email address, and we'll notify you when there's something new on the PLACARD Trial: CXD101 + Pembrolizumab in DLBCL page.